These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 28223229)

  • 1. Theranostic of biopharmaceuticals.
    Chaigne B; Watier H
    Pharmacol Ther; 2017 Jul; 175():67-74. PubMed ID: 28223229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infections associated with monoclonal antibody and fusion protein therapy in humans.
    Uettwiller F; Rigal E; Hoarau C
    MAbs; 2011; 3(5):461-6. PubMed ID: 21822056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
    Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
    J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Harnessing Fc receptor biology in the design of therapeutic antibodies.
    Sondermann P; Szymkowski DE
    Curr Opin Immunol; 2016 Jun; 40():78-87. PubMed ID: 27038127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variability factors in the clinical response to recombinant antibodies and IgG Fc-containing fusion proteins.
    Watier H
    Expert Opin Biol Ther; 2005 Sep; 5 Suppl 1():S29-36. PubMed ID: 16187938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fcγ1 fragment of IgG1 as a powerful affinity tag in recombinant Fc-fusion proteins: immunological, biochemical and therapeutic properties.
    Soleimanpour S; Hassannia T; Motiee M; Amini AA; Rezaee SA
    Crit Rev Biotechnol; 2017 May; 37(3):371-392. PubMed ID: 27049690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein.
    Moreland LW; Baumgartner SW; Schiff MH; Tindall EA; Fleischmann RM; Weaver AL; Ettlinger RE; Cohen S; Koopman WJ; Mohler K; Widmer MB; Blosch CM
    N Engl J Med; 1997 Jul; 337(3):141-7. PubMed ID: 9219699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic proteins.
    Dimitrov DS
    Methods Mol Biol; 2012; 899():1-26. PubMed ID: 22735943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next-generation Fc chimeric proteins: avoiding immune-system interactions.
    Junghans RP
    Trends Biotechnol; 1997 May; 15(5):155. PubMed ID: 9161048
    [No Abstract]   [Full Text] [Related]  

  • 10. Advances in the assessment and control of the effector functions of therapeutic antibodies.
    Jiang XR; Song A; Bergelson S; Arroll T; Parekh B; May K; Chung S; Strouse R; Mire-Sluis A; Schenerman M
    Nat Rev Drug Discov; 2011 Feb; 10(2):101-11. PubMed ID: 21283105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunogenicity of biopharmaceuticals: Which consequences during the treatment of rheumatoid arthritis?].
    Goupille P
    Rev Med Interne; 2016 May; 37(5):343-9. PubMed ID: 26526777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancing the potency of therapeutic monoclonal antibodies via Fc optimization.
    Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Johnson S; Koenig S; Bonvini E
    Adv Enzyme Regul; 2008; 48():152-64. PubMed ID: 18177741
    [No Abstract]   [Full Text] [Related]  

  • 13. Adalimumab-associated multiple sclerosis.
    Bensouda-Grimaldi L; Mulleman D; Valat JP; Autret-Leca E
    J Rheumatol; 2007 Jan; 34(1):239-40; discussion 240. PubMed ID: 17216704
    [No Abstract]   [Full Text] [Related]  

  • 14. Fc fusion as a platform technology: potential for modulating immunogenicity.
    Levin D; Golding B; Strome SE; Sauna ZE
    Trends Biotechnol; 2015 Jan; 33(1):27-34. PubMed ID: 25488117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Dulaglutide and liraglutide compared].
    Bruhn C
    Med Monatsschr Pharm; 2015 May; 38(5):198-9. PubMed ID: 26364414
    [No Abstract]   [Full Text] [Related]  

  • 16. Functional Role of Carbohydrate Residues in Human Immunoglobulin G and Therapeutic Monoclonal Antibodies.
    Dorokhov YL; Sheshukova EV; Kosobokova EN; Shindyapina AV; Kosorukov VS; Komarova TV
    Biochemistry (Mosc); 2016 Aug; 81(8):835-57. PubMed ID: 27677552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologic drugs for the treatment of hidradenitis suppurativa: an evidence-based review.
    Shuja F; Chan CS; Rosen T
    Dermatol Clin; 2010 Jul; 28(3):511-21, 523-4; quiz 522-3. PubMed ID: 20510761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group.
    Fisher CJ; Agosti JM; Opal SM; Lowry SF; Balk RA; Sadoff JC; Abraham E; Schein RM; Benjamin E
    N Engl J Med; 1996 Jun; 334(26):1697-702. PubMed ID: 8637514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept.
    Weinberg JM; Saini R; Tutrone WD
    J Drugs Dermatol; 2002 Dec; 1(3):303-10. PubMed ID: 12851990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New monoclonal antibodies to prevent transplant rejection.
    Med Lett Drugs Ther; 1998 Sep; 40(1036):93-4. PubMed ID: 9774964
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.